News

Submission of proposals: problems and complaint procedure

Published on | 4 years ago

Programmes Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Horizon Europe

The COM has informed the following:

The current problems in the submission system are mainly due to the extremely high traffic that the system currently suffers in conjunction with an unfortunate chain of incidents linked to the global infrastructure that supports it. 

Main incidents reported:

  • Issues with saving form or cannot submit proposal
  • Issues in the print preview of the proposal when there is a high number of participants
  • Incapacity of changing participant order

It is essential that participants take screenshots before the call deadline and if submission did not succeed, submit a complaint within four days after the call deadline 

Instructions are given in the online manual 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1743 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.